AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1483371 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 0.1%
Number of subjects: 164
Study 1483371 — intervention group
Group type: COMPARATOR
Intervention: Control group D (no NSAID)
Number of subjects: 164
Study 3881220 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 8
Study 3881220 — intervention group
Group type: COMPARATOR
Intervention: Doxapram
Number of subjects: 8
Study 31711211 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intensity intervention (graded exercise test, feedback-monitoring devices)
Number of subjects: 10
Study 31711211 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intensity intervention
Number of subjects: 10
Study 31711211 — intervention group
Group type: COMPARATOR
Intervention: Therapists' perspective
Number of subjects: 10
Study 31711211 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient perceptions
Number of subjects: 10
Study 31711211 — intervention group
Group type: COMPARATOR
Intervention: Therapists' perceptions
Number of subjects: 10
Study 31894030 — intervention group
Group type: EXPERIMENTAL
Intervention: 5mg amlodipine
Number of subjects: 84
Study 31894030 — intervention group
Group type: COMPARATOR
Intervention: 2.5mg levamlodipine
Number of subjects: 84
Study 28903120 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural case management (CBCM)
Number of subjects: 268
Study 25287762 — intervention group
Group type: EXPERIMENTAL
Intervention: Orodispersible L-carnosine (500 mg OD)
Number of subjects: 50
Study 23426674 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereo plaids presentation
Number of subjects: 0
Study 23426674 — intervention group
Group type: EXPERIMENTAL
Intervention: Different spatial frequency and contrast gratings
Number of subjects: 0
Study 21194693 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg lycopene daily for 8 weeks
Number of subjects: 126
Study 21194693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 21194693 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg lycopene daily for 8 weeks
Number of subjects: 126
Study 18321372 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior approach technique
Number of subjects: 150
Study 18321372 — intervention group
Group type: COMPARATOR
Intervention: Conventional liver resection
Number of subjects: 150
Study 17128339 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (part of the WHO trial for prevention of pre-eclampsia)
Number of subjects: 7993
Study 13678475 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (ALN) 70 mg once weekly
Number of subjects: 549
Study 13678475 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate (RIS) 5 mg daily
Number of subjects: 549
Study 13678475 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 549
Study 11139370 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic sclerosis patients
Number of subjects: 34
Study 11139370 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study 9003923 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadodiamide injection
Number of subjects: 353
Study 9003923 — intervention group
Group type: COMPARATOR
Intervention: Gadopentetate dimeglumine (Magnevist)
Number of subjects: 353
Study 1467102 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-gauge Whitacre needle
Number of subjects: 150
Study 1467102 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-gauge Whitacre needle
Number of subjects: 150
Study 1467102 — intervention group
Group type: EXPERIMENTAL
Intervention: 26-gauge Quincke needle
Number of subjects: 150
Study 1467102 — intervention group
Group type: EXPERIMENTAL
Intervention: More than two needle insertions
Number of subjects: 150
Study 1467102 — intervention group
Group type: COMPARATOR
Intervention: Two or less needle insertions
Number of subjects: 150
Study 6426377 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care medication program
Number of subjects: 0
Study 30767274 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab (1,200 mg every 2 weeks for 22.7 months [median])
Number of subjects: 117
Study 30767274 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 117
Study 30767274 — intervention group
Group type: COMPARATOR
Intervention: Eculizumab (for patients who received placebo during REGAIN)
Number of subjects: 117
Study 30266120 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification combined with intraocular lens implantation
Number of subjects: 152
Study 30266120 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 152
Study 28163732 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard physical therapy and dry needling (DN)
Number of subjects: 58
Study 28163732 — intervention group
Group type: COMPARATOR
Intervention: Standard physical therapy
Number of subjects: 58
Study 24142752 — intervention group
Group type: EXPERIMENTAL
Intervention: Centre-based cardiac rehabilitation (Group A)
Number of subjects: 53
Study 24142752 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid model of training (Group B)
Number of subjects: 53
Study 24142752 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Group A and Group B)
Number of subjects: 53
Study 22324419 — intervention group
Group type: EXPERIMENTAL
Intervention: ICP-ABP wave amplitude correlation (IAAC)
Number of subjects: 94
Study 22324419 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure reactivity index (PRx)
Number of subjects: 94
Study 22324419 — intervention group
Group type: EXPERIMENTAL
Intervention: IAAC with average ≥ 0.2
Number of subjects: 94
Study 19678781 — intervention group
Group type: EXPERIMENTAL
Intervention: Sour tea (Hibiscus sabdariffa), consumed two times a day for 1 month
Number of subjects: 60
Study 19678781 — intervention group
Group type: COMPARATOR
Intervention: Black tea, consumed two times a day for 1 month
Number of subjects: 60
Study 17475954 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative hepatobiliary scintigraphy measuring (99m)Tc-mebrofenin uptake in the future remnant liver.
Number of subjects: 46
Study 17475954 — intervention group
Group type: COMPARATOR
Intervention: CT volumetric measurement of the future remnant liver.
Number of subjects: 46
Study 14996106 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracaine gel (4% w/w)
Number of subjects: 42
Study 14996106 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo) gel
Number of subjects: 42
Study 11426362 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifugal pump (group C, n = 57)
Number of subjects: 113
Study 11426362 — intervention group
Group type: COMPARATOR
Intervention: Roller pump (group R, n = 56)
Number of subjects: 113
Study 8996118 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim-mobilized peripheral-blood progenitor cell transplantation (PBPCT)
Number of subjects: 58
Study 8996118 — intervention group
Group type: COMPARATOR
Intervention: Autologous bone marrow transplantation (ABMT)
Number of subjects: 58
Study 8315224 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral arginine (3 g) plus lysine (3 g) taken twice daily for 14 days
Number of subjects: 16
Study 8315224 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules taken twice daily for 14 days
Number of subjects: 16
Study 3732582 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin administered according to a three-dose, 12 h regimen, first injection given immediately after clamping of the umbilical cord.
Number of subjects: 150
Study 3732582 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin group
Number of subjects: 150
Study 3732582 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 150
Study 30588573 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral activated charcoal (OAC)
Number of subjects: 97
Study 30588573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 30588573 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (CC)
Number of subjects: 97
Study 30588573 — intervention group
Group type: COMPARATOR
Intervention: Lanthanum carbonate (LC)
Number of subjects: 97
Study 27834756 — intervention group
Group type: EXPERIMENTAL
Intervention: Migalastat
Number of subjects: 57
Study 27834756 — intervention group
Group type: COMPARATOR
Intervention: ERT
Number of subjects: 57
Study 27100025 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic gastrectomy
Number of subjects: 311
Study 27100025 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic gastrecty
Number of subjects: 311
Study 27100025 — intervention group
Group type: COMPARATOR
Intervention: Open gastrectomy
Number of subjects: 311
Study 23347094 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time visual feedback on knee abduction moments during double-leg jump landings
Number of subjects: 21
Study 23347094 — intervention group
Group type: COMPARATOR
Intervention: No real-time feedback during double-leg jump landings (Control)
Number of subjects: 21
Study 23347094 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 21
Study 22060105 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (0.15 U/kg/die for 18 months)
Number of subjects: 34
Study 22060105 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 34
Study 18972170 — intervention group
Group type: EXPERIMENTAL
Intervention: CA 19-9 velocity
Number of subjects: 96
Study 18972170 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CA 19-9 levels
Number of subjects: 96
Study 18972170 — intervention group
Group type: EXPERIMENTAL
Intervention: CA 19-9 velocity at disease progression
Number of subjects: 96
Study 18972170 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 96
Study 18972170 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-free survival
Number of subjects: 96
Study 17223061 — intervention group
Group type: EXPERIMENTAL
Intervention: Instant vision
Number of subjects: 60
Study 17223061 — intervention group
Group type: COMPARATOR
Intervention: Patching
Number of subjects: 60
Study 17223061 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 60
Study 14980293 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal CPAP
Number of subjects: 0
Study 14980293 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPPV
Number of subjects: 0
Study 14980293 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy
Number of subjects: 0
Study 14980293 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone
Number of subjects: 0
Study 14980293 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylxanthines
Number of subjects: 0
Study 12101333 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-suction (Jackson-Pratt) drains inserted into the peritoneal cavity and cul-de-sac
Number of subjects: 324
Study 12101333 — intervention group
Group type: COMPARATOR
Intervention: No drains
Number of subjects: 324
Study 10519166 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutaneous aspirin (750 mg/day for 10 days)
Number of subjects: 0
Study 10519166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10519166 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutaneous aspirin
Number of subjects: 0
Study 7627341 — intervention group
Group type: EXPERIMENTAL
Intervention: Normocaloric meal
Number of subjects: 0
Study 7627341 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric, isobulk meal
Number of subjects: 0
Study 1674632 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (5 mg)
Number of subjects: 17
Study 1674632 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (6 mg)
Number of subjects: 17
Study 7014105 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg xipamide
Number of subjects: 0
Study 7014105 — intervention group
Group type: COMPARATOR
Intervention: 100 mg chlorthalidone
Number of subjects: 0
Study 7014105 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg xipamide after 100 mg chlorthalidone
Number of subjects: 0
Study 7014105 — intervention group
Group type: COMPARATOR
Intervention: 100 mg chlorthalidone after 40 mg xipamide
Number of subjects: 0
Study 7014105 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg xipamide and 100 mg chlorthalidone
Number of subjects: 0
Study 31475696 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic injection of lidocaine in the sphenopalatine ganglion (IL; n=18)
Number of subjects: 25
Study 31475696 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic application of topical lidocaine over sphenopalatine ganglion (TL; n=7)
Number of subjects: 25
Study 31111591 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐SBIRT (n = 143)
Number of subjects: 439
Study 31111591 — intervention group
Group type: COMPARATOR
Intervention: EUC (n = 151)
Number of subjects: 439
Study 31111591 — intervention group
Group type: EXPERIMENTAL
Intervention: SBIRT (n = 145)
Number of subjects: 439
Study 28091647 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytosterol-enriched spread
Number of subjects: 0
Study 28091647 — intervention group
Group type: COMPARATOR
Intervention: Regular spread
Number of subjects: 0
Study 26452230 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint‐induced movement therapy plus electrical stimulation
Number of subjects: 68
Study 26452230 — intervention group
Group type: COMPARATOR
Intervention: Constraint‐induced movement therapy
Number of subjects: 68
Study 26452230 — intervention group
Group type: COMPARATOR
Intervention: Traditional occupational therapy
Number of subjects: 68
Study 23695232 — intervention group
Group type: EXPERIMENTAL
Intervention: Garenoxacin (GRNX) 400 mg/day for 4 days
Number of subjects: 108
Study 23695232 — intervention group
Group type: COMPARATOR
Intervention: SBT/ABPC (sulbactam/ampicillin) 6 g/day for 3 days followed by continuous administration for 4 days
Number of subjects: 108
Study 21293305 — intervention group
Group type: EXPERIMENTAL
Intervention: High-load (HL) squat protocol (3 repetitions at 90% 1RM)
Number of subjects: 11
Study 21293305 — intervention group
Group type: COMPARATOR
Intervention: High-volume (HV) squat protocol (12 repetitions at 37% 1RM)
Number of subjects: 11
Study 19660516 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth Mousse (CPP-ACP paste) applied for 3 min at 0, 8, 24, and 36 h after demineralization with soft drink (Coca Cola)
Number of subjects: 30
Study 19660516 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth Mousse (CPP-ACP paste) applied for 3 min without prior demineralization (intact enamel)
Number of subjects: 30
Study 19660516 — intervention group
Group type: COMPARATOR
Intervention: Demineralization with soft drink (Coca Cola) (4 intervals of 2 min)
Number of subjects: 30
Study 18693598 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Ultrafiltration (MUF)
Number of subjects: 96
Study 18693598 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 96
Study 15296473 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE/MPA (0.625 mg conjugated equine estrogen plus 5 mg medroxyprogesterone acetate), n=34
Number of subjects: 146
Study 15296473 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg), n=37
Number of subjects: 146
Study 15296473 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg), n=40
Number of subjects: 146
Study 15296473 — intervention group
Group type: COMPARATOR
Intervention: Control group (no active treatment), n=35
Number of subjects: 146
Study 10924298 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/day) and Ticlopidine (2x250 mg/day)
Number of subjects: 40
Study 10924298 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/day) and Phenprocoumon (INR 2.0-3.0) with Dipyridamole (3x160 mg/day)
Number of subjects: 40
Study 10924298 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein plasma levels
Number of subjects: 40
Study 8820550 — intervention group
Group type: EXPERIMENTAL
Intervention: Unemployed subjects
Number of subjects: 150
Study 8820550 — intervention group
Group type: EXPERIMENTAL
Intervention: Part-time employment subjects
Number of subjects: 150
Study 8820550 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-time employment subjects
Number of subjects: 150
Study 8820550 — intervention group
Group type: EXPERIMENTAL
Intervention: Second sample subjects
Number of subjects: 150
Study 1576619 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 41
Study 1576619 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole (TMP/SMX)
Number of subjects: 41
Study 1576619 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus vaginal suppositories
Number of subjects: 41
Study 1576619 — intervention group
Group type: COMPARATOR
Intervention: Sterilized skim-milk suppositories
Number of subjects: 41
Study 6732403 — intervention group
Group type: EXPERIMENTAL
Intervention: Group management plus feedback
Number of subjects: 48
Study 6732403 — intervention group
Group type: COMPARATOR
Intervention: Advice
Number of subjects: 48
Study 6732403 — intervention group
Group type: COMPARATOR
Intervention: Intensive educational program
Number of subjects: 48
Study 3691914 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 or 3% topical minoxidil applied twice daily for 12 months
Number of subjects: 56
Study 3691914 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% topical minoxidil (Regaine) applied twice daily for 1 year
Number of subjects: 56
Study 31474161 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal CO2 laser therapy
Number of subjects: 0
Study 31474161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28741622 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP-115 (80 mg daily for 6, 10, or 14 days)
Number of subjects: 6
Study 28741622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 27259391 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracapsular tranexamic acid
Number of subjects: 131
Study 27259391 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tranexamic acid
Number of subjects: 131
Study 27259391 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 131
Study 25480542 — intervention group
Group type: EXPERIMENTAL
Intervention: Low/moderate education group
Number of subjects: 1342
Study 25480542 — intervention group
Group type: COMPARATOR
Intervention: High education group
Number of subjects: 1342
Study 25480542 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitude towards consuming vegetables and availability of vegetables at home
Number of subjects: 1342
Study 23275042 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose octreotide (50 μg/h × 3d + 25 μg/h × 4d)
Number of subjects: 372
Study 23275042 — intervention group
Group type: COMPARATOR
Intervention: Low-dose octreotide (25 μg/h × 7d)
Number of subjects: 372
Study 23275042 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose octreotide
Number of subjects: 372
Study 20132622 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site in-service clinical skills training for nurse practitioners (intervention clinics)
Number of subjects: 6510
Study 20132622 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions received by clinics (intervention clinics)
Number of subjects: 6510
Study 20132622 — intervention group
Group type: COMPARATOR
Intervention: Control clinics (no intervention)
Number of subjects: 6510
Study 18606428 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Directly Observed Treatment (NDOT)
Number of subjects: 320
Study 18606428 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly Observed Treatment (DOT)
Number of subjects: 320
Study 16847383 — intervention group
Group type: EXPERIMENTAL
Intervention: PEFG (cisplatin, epirubicin, 5‐fluorouracil, gemcitabine)
Number of subjects: 0
Study 16847383 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine
Number of subjects: 0
Study 14650364 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranlukast 450 mg/day for 1 to 2 years
Number of subjects: 81
Study 11075740 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent implantation
Number of subjects: 123
Study 11075740 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 123
Study 11075740 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 123
Study 11075740 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent implantation and CABG
Number of subjects: 123
Study 9014622 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at blood concentrations of 1‐10 micrograms ml‐1
Number of subjects: 41
Study 9014622 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at a dose rate of 6.3‐7.8 mg kg‐1 h‐1
Number of subjects: 41
Study 9014622 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at a blood concentration of 2.9 micrograms ml‐1
Number of subjects: 41
Study 9014622 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentration and dose of propofol
Number of subjects: 41
Study 9014622 — intervention group
Group type: EXPERIMENTAL
Intervention: Latency of the Na wave
Number of subjects: 41
Study 1563214 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg t.i.d. racemic (R,S)-propranolol
Number of subjects: 10
Study 1563214 — intervention group
Group type: COMPARATOR
Intervention: 20 mg t.i.d. optically pure (S)-propranolol
Number of subjects: 10
Study 1563214 — intervention group
Group type: EXPERIMENTAL
Intervention: (R,S)-propranolol
Number of subjects: 10
Study 1563214 — intervention group
Group type: COMPARATOR
Intervention: (S)-propranolol
Number of subjects: 10
Study 3916061 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 100
Study 3916061 — intervention group
Group type: COMPARATOR
Intervention: Iopamidol
Number of subjects: 100
Study 31251706 — intervention group
Group type: EXPERIMENTAL
Intervention: Online hypnosis intervention (hypnosis mp3s)
Number of subjects: 43
Study 31251706 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 43
Study 29357902 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT with 30Gy in ten fractions
Number of subjects: 120
Study 29357902 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT with 30Gy in ten fractions and SIB to 40Gy
Number of subjects: 120
Study 29357902 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT with 20Gy in five fractions
Number of subjects: 120